Validation of the partin nomogram for prostate cancer in a national sample
- PMID: 19913246
- DOI: 10.1016/j.juro.2009.08.143
Validation of the partin nomogram for prostate cancer in a national sample
Abstract
Purpose: The Partin tables are a nomogram that is widely used to discriminate prostate cancer pathological stages, given common preoperative clinical characteristics. The nomogram is based on patients undergoing radical prostatectomy at The Johns Hopkins Medical Institutions. We validated the Partin tables in a large, population based sample.
Materials and methods: The National Cancer Institute Surveillance, Epidemiology and End Results database was used to identify patients treated from 2004 to 2005 who underwent radical prostatectomy. The 2007 Partin tables were used to estimate the prevalence of positive lymph nodes, seminal vesicle invasion, extraprostatic extension and organ confined disease in men with prostate cancer in the database using clinical stage, preoperative prostate specific antigen and Gleason score. The discriminative ability of the tables was explored by constructing ROC curves.
Results: We identified 11,185 men who underwent radical prostatectomy for prostate cancer in 2004 to 2005. The Partin tables discriminated well between patient groups at risk for positive lymph nodes and seminal vesicle invasion (AUC 0.77 and 0.74, respectively). The discrimination of extraprostatic extension and organ confined disease was more limited (AUC 0.62 and 0.68, respectively). The AUC for positive lymph nodes was 0.78 in white men, 0.73 in black men and 0.83 in Asian/Pacific Islander men (p = 0.17). The AUC for positive lymph nodes in men 61 years old or younger was 0.80 vs 0.74 in men older than 61 years (p = 0.03).
Conclusions: The Partin tables showed excellent discrimination for seminal vesicle invasion and positive lymph nodes. Discrimination of extraprostatic extension and organ confined disease was more limited. The Partin tables performed best in young men.
Comment in
-
Re: Validation of the Partin nomogram for prostate cancer in a national sample: J. B. Yu, D. V. Makarov, R. Sharma, R. E. Peschel, A. W. Partin and C. P. Gross J Urol 2010; 183: 105-111.J Urol. 2010 Oct;184(4):1571-2; author reply 1572-3. doi: 10.1016/j.juro.2010.06.029. Epub 2010 Aug 21. J Urol. 2010. PMID: 20732697 No abstract available.
Similar articles
-
Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.J Urol. 2008 Sep;180(3):904-9; discussion 909-10. doi: 10.1016/j.juro.2008.05.047. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635221
-
Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.BJU Int. 2017 May;119(5):676-683. doi: 10.1111/bju.13573. Epub 2016 Jul 29. BJU Int. 2017. PMID: 27367645
-
Nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: comparison with western predictive tools using decision curve analysis.Int J Urol. 2012 Sep;19(9):846-52. doi: 10.1111/j.1442-2042.2012.03040.x. Epub 2012 May 15. Int J Urol. 2012. PMID: 22587373
-
Reliability of the different versions of Partin tables in predicting extraprostatic extension of prostate cancer: a systematic review and meta-analysis.Minerva Urol Nefrol. 2019 Oct;71(5):457-478. doi: 10.23736/S0393-2249.19.03427-1. Epub 2019 Apr 5. Minerva Urol Nefrol. 2019. PMID: 30957478
-
Predictive models and prostate cancer.Nat Clin Pract Urol. 2008 Feb;5(2):82-92. doi: 10.1038/ncpuro0972. Nat Clin Pract Urol. 2008. PMID: 18259186 Review.
Cited by
-
Prostate cancer cell phenotypes based on AGR2 and CD10 expression.Mod Pathol. 2013 Jun;26(6):849-59. doi: 10.1038/modpathol.2012.238. Epub 2013 Jan 25. Mod Pathol. 2013. PMID: 23348903 Free PMC article.
-
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.BJU Int. 2011 May;107(10):1562-9. doi: 10.1111/j.1464-410X.2010.09692.x. Epub 2010 Sep 28. BJU Int. 2011. PMID: 20875091 Free PMC article.
-
Treatment of localized prostate cancer: when is active surveillance appropriate?Nat Rev Clin Oncol. 2010 Jul;7(7):394-400. doi: 10.1038/nrclinonc.2010.63. Epub 2010 May 4. Nat Rev Clin Oncol. 2010. PMID: 20440282 Review.
-
Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer.World J Mens Health. 2021 Jan;39(1):38-47. doi: 10.5534/wjmh.200030. Epub 2020 Jun 24. World J Mens Health. 2021. PMID: 32648376 Free PMC article. Review.
-
ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.Oncol Lett. 2016 Apr;11(4):2532-2538. doi: 10.3892/ol.2016.4282. Epub 2016 Feb 25. Oncol Lett. 2016. PMID: 27073512 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical